Lead Product(s): LB-P8
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: LB-P8
Highest Development Status: Preclinical Product Type: Large molecule
Deal Size: $21.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 26, 2021
LISCure is developing the world's first microbiome-based NASH(non-alcoholic steatohepatitis) treatment, LB-P8, as well as the rheumatoid arthritis treatment, LB-P6, for global clinical trials.